TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
14.345 USD
+0.06 (+0.38%)
We assign a fundamental rating of 5 out of 10 to TAK. TAK was compared to 192 industry peers in the Pharmaceuticals industry. While TAK belongs to the best of the industry regarding profitability, there are concerns on its financial health. TAK is not valued too expensively and it also shows a decent growth rate. Finally TAK also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year TAK was profitable.
TAK had a positive operating cash flow in the past year.
Each year in the past 5 years TAK has been profitable.
Each year in the past 5 years TAK had a positive operating cash flow.
1.2 Ratios
TAK's Return On Assets of 0.23% is fine compared to the rest of the industry. TAK outperforms 78.65% of its industry peers.
Looking at the Return On Equity, with a value of 0.46%, TAK belongs to the top of the industry, outperforming 80.21% of the companies in the same industry.
TAK has a Return On Invested Capital of 1.87%. This is in the better half of the industry: TAK outperforms 78.65% of its industry peers.
The Average Return On Invested Capital over the past 3 years for TAK is significantly below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
Looking at the Profit Margin, with a value of 0.75%, TAK is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
In the last couple of years the Profit Margin of TAK has grown nicely.
TAK's Operating Margin of 8.46% is fine compared to the rest of the industry. TAK outperforms 79.69% of its industry peers.
In the last couple of years the Operating Margin of TAK has grown nicely.
TAK has a better Gross Margin (64.60%) than 72.92% of its industry peers.
In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TAK is still creating some value.
The number of shares outstanding for TAK has been increased compared to 1 year ago.
Compared to 5 years ago, TAK has more shares outstanding
Compared to 1 year ago, TAK has an improved debt to assets ratio.
2.2 Solvency
TAK has an Altman-Z score of 1.14. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
TAK has a Altman-Z score (1.14) which is comparable to the rest of the industry.
The Debt to FCF ratio of TAK is 5.04, which is a neutral value as it means it would take TAK, 5.04 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of TAK (5.04) is better than 82.29% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that TAK is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.61, TAK is not doing good in the industry: 67.19% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.14 |
ROIC/WACC1.17
WACC1.6%
2.3 Liquidity
A Current Ratio of 1.36 indicates that TAK should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.36, TAK is doing worse than 72.92% of the companies in the same industry.
TAK has a Quick Ratio of 1.36. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
TAK has a Quick ratio of 0.76. This is amonst the worse of the industry: TAK underperforms 85.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
TAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.38%.
Measured over the past years, TAK shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.20% on average per year.
TAK shows a decrease in Revenue. In the last year, the revenue decreased by -2.84%.
The Revenue has been growing slightly by 6.84% on average over the past years.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
TAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.50% yearly.
The Revenue is expected to grow by 0.19% on average over the next years.
EPS Next Y112.39%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
EPS Next 5YN/A
Revenue Next Year-1.23%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 204.93, which means the current valuation is very expensive for TAK.
TAK's Price/Earnings ratio is a bit cheaper when compared to the industry. TAK is cheaper than 76.56% of the companies in the same industry.
TAK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.15.
The Price/Forward Earnings ratio is 20.41, which indicates a rather expensive current valuation of TAK.
TAK's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TAK is cheaper than 77.08% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.22, TAK is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 204.93 | ||
| Fwd PE | 20.41 |
4.2 Price Multiples
TAK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TAK is cheaper than 88.54% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 92.71% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.67 | ||
| EV/EBITDA | 9.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates TAK does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of TAK may justify a higher PE ratio.
A more expensive valuation may be justified as TAK's earnings are expected to grow with 51.50% in the coming years.
PEG (NY)1.82
PEG (5Y)10.67
EPS Next 2Y79.28%
EPS Next 3Y51.5%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.46%, TAK is a good candidate for dividend investing.
TAK's Dividend Yield is rather good when compared to the industry average which is at 6.81. TAK pays more dividend than 96.35% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, TAK pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
5.2 History
The dividend of TAK has a limited annual growth rate of 1.18%.
TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
935.06% of the earnings are spent on dividend by TAK. This is not a sustainable payout ratio.
The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP935.06%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
NYSE:TAK (12/3/2025, 12:06:07 PM)
14.345
+0.06 (+0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.43%
Inst Owner Change8.68%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap45.32B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts73.68
Price Target16.25 (13.28%)
Short Float %0.34%
Short Ratio3.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.46% |
Yearly Dividend0.62
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)-7.92%
PT rev (3m)-6.18%
EPS NQ rev (1m)3.88%
EPS NQ rev (3m)11.23%
EPS NY rev (1m)-5.98%
EPS NY rev (3m)-4.73%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.02%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-0.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 204.93 | ||
| Fwd PE | 20.41 | ||
| P/S | 1.6 | ||
| P/FCF | 7.67 | ||
| P/OCF | 5.9 | ||
| P/B | 0.99 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.75 |
EPS(TTM)0.07
EY0.49%
EPS(NY)0.7
Fwd EY4.9%
FCF(TTM)1.87
FCFY13.04%
OCF(TTM)2.43
OCFY16.96%
SpS8.96
BVpS14.46
TBVpS-3.25
PEG (NY)1.82
PEG (5Y)10.67
Graham Number4.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.14 |
F-Score6
WACC1.6%
ROIC/WACC1.17
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y112.39%
EPS Next 2Y79.28%
EPS Next 3Y51.5%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.23%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.19%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year445.18%
EBIT Next 3Y77.79%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the ChartMill fundamental rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for TAK stock?
The Earnings per Share (EPS) of TAKEDA PHARMACEUTIC-SP ADR (TAK) is expected to grow by 112.39% in the next year.
How sustainable is the dividend of TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The dividend rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 7 / 10 and the dividend payout ratio is 935.06%.